AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9834259 — intervention group
Group type: COMPARATOR
Intervention: Placebo at bedtime
Number of subjects: 12
Study 9834259 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole at bedtime
Number of subjects: 12
Study 7930273 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (1) streptokinase with intravenous heparin; (2) streptokinase with subcutaneous heparin; (3) accelerated-dose rt-PA with intravenous heparin; (4) combination of streptokinase and conventionally dosed rt-PA with intravenous heparin
Number of subjects: 559
Study 3207350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice per day
Number of subjects: 8
Study 3207350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg in a single dose at night
Number of subjects: 8
Study 3207350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31868719 — intervention group
Group type: EXPERIMENTAL
Intervention: International Diabetes Federation (IDF) diagnostic criteria
Number of subjects: 163
Study 31868719 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO diagnostic criteria
Number of subjects: 163
Study 31868719 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA diagnostic criteria
Number of subjects: 163
Study 31868719 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP diagnostic criteria
Number of subjects: 163
Study 31868719 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP ATPIII diagnostic criteria
Number of subjects: 163
Study 31868719 — intervention group
Group type: COMPARATOR
Intervention: Regular exercise
Number of subjects: 163
Study 31868719 — intervention group
Group type: COMPARATOR
Intervention: Working hours
Number of subjects: 163
Study 31427877 — intervention group
Group type: COMPARATOR
Intervention: 2×day stretch training
Number of subjects: 0
Study 31427877 — intervention group
Group type: COMPARATOR
Intervention: 1×day stretch training
Number of subjects: 0
Study 28644348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose mannitol ratio (L:M) test
Number of subjects: 539
Study 28644348 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phase proteins (C-reactive protein >5 mg/L or α-1 acid glycoprotein >100 mg/dL)
Number of subjects: 539
Study 28644348 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloperoxidase and α-1 antitrypsin correlation
Number of subjects: 539
Study 28644348 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-factor partial least squares model with L:M as dependent variable
Number of subjects: 539
Study 28644348 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted models for L:M
Number of subjects: 539
Study 28644348 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammation
Number of subjects: 539
Study 26564807 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Taping Concept (MTC) covering T-11 and T-12 dermatomes
Number of subjects: 129
Study 26564807 — intervention group
Group type: COMPARATOR
Intervention: Another taping in both greater trochanter areas
Number of subjects: 129
Study 23657486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 44
Study 23657486 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (50 mg)
Number of subjects: 44
Study 23657486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23657486 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 44
Study 21442636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide therapy
Number of subjects: 32
Study 19789514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 0.5 mg/kg ketamine and peritonsillar 0.25% bupivacaine (3-5 ml per tonsil)
Number of subjects: 90
Study 19789514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saline and peritonsillar bupivacaine
Number of subjects: 90
Study 19789514 — intervention group
Group type: COMPARATOR
Intervention: Intravenous and peritonsillar saline solution (placebo)
Number of subjects: 90
Study 16794136 — intervention group
Group type: EXPERIMENTAL
Intervention: IV bolus injection of 2 mL/kg of nonionic iodine contrast material (300 mg I/mL) at 4 mL/s
Number of subjects: 171
Study 12560759 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat (3.06 g/day)
Number of subjects: 28
Study 12560759 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium fat (16.56 g/day)
Number of subjects: 28
Study 12560759 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat (30.06 g/day)
Number of subjects: 28
Study 10678628 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV (Group A)
Number of subjects: 30
Study 10678628 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy only (Group B)
Number of subjects: 30
Study 9496210 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective wrap
Number of subjects: 20
Study 9496210 — intervention group
Group type: COMPARATOR
Intervention: Non-reflective wrap
Number of subjects: 20
Study 8407387 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic lymphatic pump
Number of subjects: 42
Study 8407387 — intervention group
Group type: COMPARATOR
Intervention: Incentive spirometry
Number of subjects: 42
Study 3954249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory muscle endurance training (VMET)
Number of subjects: 32
Study 3954249 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive pressure breathing (IPPB)
Number of subjects: 32
Study 30636490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent infusion of N-Acetylcysteine (IV: 25 mg/kg bolus and then 25 mg/kg/8 hours 3 times)
Number of subjects: 60
Study 30636490 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of N-Acetylcysteine (IV: 25 mg/kg bolus and then 75 mg/kg over 24 hours)
Number of subjects: 60
Study 30636490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30772477 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU/kg C1‐INH(SC) twice per week
Number of subjects: 126
Study 30772477 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 IU/kg C1‐INH(SC) twice per week
Number of subjects: 126
Study 30772477 — intervention group
Group type: COMPARATOR
Intervention: C1‐INH(SC) (both doses)
Number of subjects: 126
Study 28578679 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 hours of additional trunk exercises for 1 hour a day, 4 days a week for 4 weeks
Number of subjects: 60
Study 28578679 — intervention group
Group type: COMPARATOR
Intervention: Cognitive exercises for 1 hour a day, 4 days a week for 4 weeks
Number of subjects: 60
Study 28578679 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 hours of additional trunk exercises
Number of subjects: 60
Study 28578679 — intervention group
Group type: COMPARATOR
Intervention: Cognitive exercises
Number of subjects: 60
Study 26138259 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg daily for 13 weeks)
Number of subjects: 154
Study 26138259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 26138259 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 154
Study 24174172 — intervention group
Group type: EXPERIMENTAL
Intervention: AGSAV301
Number of subjects: 29
Study 24174172 — intervention group
Group type: COMPARATOR
Intervention: Exforge
Number of subjects: 29
Study 24174172 — intervention group
Group type: EXPERIMENTAL
Intervention: AGSAV301 and Exforge
Number of subjects: 29
Study 20946414 — intervention group
Group type: EXPERIMENTAL
Intervention: 222G/N variants in patients admitted to the intensive-care unit (ICU)
Number of subjects: 131
Study 20946414 — intervention group
Group type: COMPARATOR
Intervention: 222G/N variants in hospitalized patients in other units
Number of subjects: 131
Study 20946414 — intervention group
Group type: COMPARATOR
Intervention: 222G/N variants in community patients
Number of subjects: 131
Study 20946414 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus load in the lower respiratory tract
Number of subjects: 131
Study 20946414 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of illness in severe infection patients
Number of subjects: 131
Study 19296244 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX7 neoadjuvant chemotherapy
Number of subjects: 15
Study 19296244 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic treatment (control group)
Number of subjects: 15
Study 19296244 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX7 neoadjuvant chemotherapy followed by laparoscopic treatment
Number of subjects: 15
Study 17437804 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 4579
Study 17437804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4579
Study 15156070 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbatrol (CBR) at dosages of 800, 1200, 1600 mg/day
Number of subjects: 47
Study 15156070 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid (VPA)
Number of subjects: 47
Study 11733868 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 5
Study 11733868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 9571389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral approach with structured contingency management intervention (experimental condition)
Number of subjects: 40
Study 9571389 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control condition)
Number of subjects: 40
Study 7810041 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated static perimetry
Number of subjects: 232
Study 7810041 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic perimetry
Number of subjects: 232
Study 3290356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin treatment for 5 weeks
Number of subjects: 13
Study 3290356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin treatment
Number of subjects: 13
Study 30602192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided caudal block (Group H)
Number of subjects: 266
Study 30602192 — intervention group
Group type: COMPARATOR
Intervention: Conventional caudal block (Group C)
Number of subjects: 266
Study 27539402 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional weight-bearing mobilization
Number of subjects: 56
Study 27539402 — intervention group
Group type: COMPARATOR
Intervention: Non-weight-bearing cast immobilization
Number of subjects: 56
Study 25761552 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles (CNs)
Number of subjects: 55
Study 25761552 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 24177681 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise
Number of subjects: 19
Study 24177681 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to high intensity aerobic and resistance exercises
Number of subjects: 19
Study 24177681 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine physiotherapy)
Number of subjects: 19
Study 20960149 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of indwelling catheterization
Number of subjects: 246
Study 20960149 — intervention group
Group type: COMPARATOR
Intervention: 5 days of indwelling catheterization
Number of subjects: 246
Study 19294642 — intervention group
Group type: EXPERIMENTAL
Intervention: 2dTCA (two-dimensional temporal clustering algorithm)
Number of subjects: 12
Study 19294642 — intervention group
Group type: COMPARATOR
Intervention: Event-related activation using known timing
Number of subjects: 12
Study 17687099 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment strategies including mucolytic agents, physiotherapy, exercise, antibiotics, nutritional strategies, anti-inflammatory treatments, and vaccinations against common respiratory pathogens.
Number of subjects: 0
Study 15478388 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 8
Study 15280530 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist 1.0 mmol/ml)
Number of subjects: 21
Study 15280530 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (Omnipaque 350)
Number of subjects: 21
Study 10572674 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (serum AFP test and ultrasound every 6 months)
Number of subjects: 18816
Study 10572674 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up screening every 6 months in screening group
Number of subjects: 18816
Study 10572674 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (not followed up every 6 months)
Number of subjects: 18816
Study 10572674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 18816
Study 7547088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg at night
Number of subjects: 24
Study 7547088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2166699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pork Insulin (PI)
Number of subjects: 30
Study 2166699 — intervention group
Group type: COMPARATOR
Intervention: Human Insulin (HI)
Number of subjects: 30
Study 2166699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pork Insulin (PI) after 20 min of hypoglycemia
Number of subjects: 30
Study 2166699 — intervention group
Group type: COMPARATOR
Intervention: Human Insulin (HI) after 20 min of hypoglycemia
Number of subjects: 30
Study 7417630 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 18
Study 7417630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7417630 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine reinstatement
Number of subjects: 18
Study 31234651 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative medicine strategies for diabetes control
Number of subjects: 85
Study 31234651 — intervention group
Group type: EXPERIMENTAL
Intervention: Home remedies, commercial weight-loss products, and herbal teas
Number of subjects: 85
Study 31234651 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of alternative methods to providers
Number of subjects: 85
Study 26505288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure to tempting unhealthy food (e.g. candy)
Number of subjects: 0
Study 26505288 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25022780 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Number of subjects: 72
Study 25022780 — intervention group
Group type: COMPARATOR
Intervention: Distracter task
Number of subjects: 72
Study 21423053 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 96
Study 21423053 — intervention group
Group type: COMPARATOR
Intervention: Vertebroplasty
Number of subjects: 96
Study 20709866 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg, 4 times/day)
Number of subjects: 24
Study 20709866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20709866 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 24
Study 17396059 — intervention group
Group type: COMPARATOR
Intervention: No Smoking (NS)
Number of subjects: 18
Study 17396059 — intervention group
Group type: COMPARATOR
Intervention: Electrically Heated Cigarette Smoking System (EHCSS)
Number of subjects: 18
Study 17396059 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Cigarettes (CC)
Number of subjects: 18
Study 15878496 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination (SFC) product (50/250 microg bid via the Diskus inhaler)
Number of subjects: 28
Study 15878496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11888872 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary radiotherapy (RT)
Number of subjects: 435
Study 11888872 — intervention group
Group type: COMPARATOR
Intervention: No axillary treatment
Number of subjects: 435
Study 11888872 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (axillary RT and no axillary treatment)
Number of subjects: 435
Study 10465075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 film
Number of subjects: 20
Study 10465075 — intervention group
Group type: COMPARATOR
Intervention: Placebo film
Number of subjects: 20
Study 7599449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic transmission velocity (UTV)
Number of subjects: 336
Study 7599449 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiffness (STF)
Number of subjects: 336
Study 7599449 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-band ultrasonic attenuation (BUA)
Number of subjects: 336
Study 7599449 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral neck BMD
Number of subjects: 336
Study 7599449 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal BMD
Number of subjects: 336
Study 29025380 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy (<= 3 days after transplant)
Number of subjects: 39
Study 29025380 — intervention group
Group type: COMPARATOR
Intervention: Late tracheostomy (> 3 days after transplant)
Number of subjects: 39
Study 28594783 — intervention group
Group type: EXPERIMENTAL
Intervention: 17α‐hydroxyprogesterone caproate (341 mg per week)
Number of subjects: 235
Study 28594783 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (200 mg per day)
Number of subjects: 235
Study 28594783 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 235
Study 26237636 — intervention group
Group type: EXPERIMENTAL
Intervention: SonicFill system/bulk fill (Group A)
Number of subjects: 80
Study 26237636 — intervention group
Group type: EXPERIMENTAL
Intervention: Herculite Ultra composite resin/incremental technique (Group C)
Number of subjects: 80
Study 26237636 — intervention group
Group type: COMPARATOR
Intervention: SonicFill system/bulk fill (Group B)
Number of subjects: 80
Study 26237636 — intervention group
Group type: COMPARATOR
Intervention: Herculite Ultra/incremental technique (Group D)
Number of subjects: 80
Study 23795769 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (15 min of moderate intensity stationary cycling)
Number of subjects: 144
Study 23795769 — intervention group
Group type: COMPARATOR
Intervention: Control (15 min completing ratings of neutral IAPS images)
Number of subjects: 144
Study 21168857 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 99
Study 21168857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 21168857 — intervention group
Group type: EXPERIMENTAL
Intervention: Kobayashi score
Number of subjects: 99
Study 18514522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue trials
Number of subjects: 16
Study 18514522 — intervention group
Group type: COMPARATOR
Intervention: No fatigue trials
Number of subjects: 16
Study 16848203 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of triamcinolone acetonide
Number of subjects: 80
Study 16848203 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone‐neomycin drops
Number of subjects: 80
Study 12765424 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab (SB 240563) anti‐IL‐5 antibody administered three times
Number of subjects: 19
Study 12765424 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 10648040 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS)
Number of subjects: 372
Study 10648040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 9752908 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection transthecal technique using 3 cc of lignocaine and bupivacaine mixture
Number of subjects: 142
Study 9752908 — intervention group
Group type: COMPARATOR
Intervention: Single injection subcutaneous technique using 3 cc of lignocaine and bupivacaine mixture
Number of subjects: 142
Study 8210390 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term low-dose erythromycin therapy (200 mg three times daily)
Number of subjects: 19
Study 8210390 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 19
Study 3333017 — intervention group
Group type: EXPERIMENTAL
Intervention: 880 mg calcium daily for 12 weeks
Number of subjects: 20
Study 3333017 — intervention group
Group type: COMPARATOR
Intervention: 5 mg stanozolol daily for 12 weeks
Number of subjects: 20
Study 31230484 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-Folic Acid (IFA) supplementation
Number of subjects: 647
Study 31230484 — intervention group
Group type: COMPARATOR
Intervention: Experiencing heartburn and vomiting
Number of subjects: 647
Study 31230484 — intervention group
Group type: COMPARATOR
Intervention: Unintended pregnancy and better education
Number of subjects: 647
Study 31230484 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptability of IFA supplement, number of antenatal care (ANC) visits, and being ever married
Number of subjects: 647
Study 29242350 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP‐guided therapy
Number of subjects: 405
Study 29242350 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 405
Study 28351407 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Fat Free Mass (FFM)
Number of subjects: 1150
Study 28351407 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Fat Free Mass (FFM) ≥ 40.76 kg (Upper quartile of participants)
Number of subjects: 1150
Study 28351407 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased maternal age
Number of subjects: 1150
Study 28351407 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased pre-pregnancy BMI
Number of subjects: 1150
Study 26160302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75 % without epinephrine (ROPI)
Number of subjects: 38
Study 26160302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75 % with epinephrine 5 μg/mL (ROPI‐EPI)
Number of subjects: 38
Study 26160302 — intervention group
Group type: COMPARATOR
Intervention: Comparison between ROPI and ROPI‐EPI
Number of subjects: 38
Study 23200554 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30-45mg/day)
Number of subjects: 54
Study 23200554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 22282728 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.3 mm-long implants
Number of subjects: 60
Study 22282728 — intervention group
Group type: COMPARATOR
Intervention: 9.3 mm or longer implants
Number of subjects: 60